146 related articles for article (PubMed ID: 18656274)
21. Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.
Marmur JD; Poludasu S; Lazar J; Cavusoglu E
Catheter Cardiovasc Interv; 2009 Feb; 73(2):214-21. PubMed ID: 19156882
[TBL] [Abstract][Full Text] [Related]
22. Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from five randomised controlled trials.
Piccolo R; Eitel I; Iversen AZ; Gu YL; Dominguez-Rodriguez A; de Smet BJ; Mahmoud KD; Abreu-Gonzalez P; Thiele H; Piscione F
EuroIntervention; 2014 Jan; 9(9):1110-20. PubMed ID: 24457282
[TBL] [Abstract][Full Text] [Related]
23. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
[TBL] [Abstract][Full Text] [Related]
24. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.
Bolognese L; Falsini G; Liistro F; Angioli P; Ducci K; Taddei T; Tarducci R; Cosmi F; Baldassarre S; Burali A
J Am Coll Cardiol; 2006 Feb; 47(3):522-8. PubMed ID: 16458130
[TBL] [Abstract][Full Text] [Related]
25. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.
Thiele H; Wöhrle J; Hambrecht R; Rittger H; Birkemeyer R; Lauer B; Neuhaus P; Brosteanu O; Sick P; Wiemer M; Kerber S; Kleinertz K; Eitel I; Desch S; Schuler G
Lancet; 2012 Mar; 379(9819):923-931. PubMed ID: 22357109
[TBL] [Abstract][Full Text] [Related]
26. Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial.
Mehilli J; Ndrepepa G; Kastrati A; Neumann FJ; ten Berg J; Bruskina O; Dotzer F; Seyfarth M; Pache J; Kufner S; Dirschinger J; Berger PB; Schömig A
Am Heart J; 2007 Jul; 154(1):158.e1-7. PubMed ID: 17584569
[TBL] [Abstract][Full Text] [Related]
27. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program.
Hassan AK; Liem SS; van der Kley F; Bergheanu SC; Wolterbeek R; Bosch J; Bootsma M; Zeppenfeld K; van der Laarse A; Atsma DE; Jukema JW; Schalij MJ
Catheter Cardiovasc Interv; 2009 Aug; 74(2):335-43. PubMed ID: 19642182
[TBL] [Abstract][Full Text] [Related]
28. Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Shimada YJ; Nakra NC; Fox JT; Kanei Y
Am J Cardiol; 2012 Mar; 109(5):624-8. PubMed ID: 22152971
[TBL] [Abstract][Full Text] [Related]
29. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel.
Schömig A; Schmitt C; Dibra A; Mehilli J; Volmer C; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Berger PB; Kastrati A;
Eur Heart J; 2005 Jul; 26(14):1379-84. PubMed ID: 15734767
[TBL] [Abstract][Full Text] [Related]
30. Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.
Gunasekara AP; Walters DL; Aroney CN
Int J Cardiol; 2006 Apr; 109(1):16-20. PubMed ID: 16014315
[TBL] [Abstract][Full Text] [Related]
31. Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Piccolo R; Eitel I; Galasso G; Iversen AZ; Gu YL; Dominguez-Rodriguez A; de Smet BJ; Mahmoud KD; Abreu-Gonzalez P; Thiele H; Piscione F
Vascul Pharmacol; 2015 Oct; 73():32-7. PubMed ID: 26071862
[TBL] [Abstract][Full Text] [Related]
32. A multicenter randomized study to evaluate intracoronary abciximab with the ClearWay catheter to improve outcomes with Lysis (IC ClearLy): trial study design and rationale.
Sardella G; Sangiorgi GM; Mancone M; Colantonio R; Donahue M; Politi L; Bucciarelli-Ducci C; Carbone I; Francone M; Ligabue G; Fiocchi F; Di Roma A; Benedetti G; Lucisano L; Stio RE; Agati L; Modena MG; Genuini I; Fedele F; Gibson M
J Cardiovasc Med (Hagerstown); 2010 Jul; 11(7):529-35. PubMed ID: 19918189
[TBL] [Abstract][Full Text] [Related]
33. [Does intracoronary abciximab improve the outcome of percutaneous coronary interventions? A randomized controlled trial].
Galache Osuna JG; Sánchez-Rubio J; Calvo I; Diarte JA; Lukic A; Placer LJ
Rev Esp Cardiol; 2006 Jun; 59(6):567-74. PubMed ID: 16790200
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials.
de Queiroz Fernandes Araújo JO; Veloso HH; Braga De Paiva JM; Filho MW; Vincenzo De Paola AA
Am Heart J; 2004 Dec; 148(6):937-43. PubMed ID: 15632875
[TBL] [Abstract][Full Text] [Related]
35. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.
Marmur JD; Mitre CA; Barnathan E; Cavusoglu E
Am Heart J; 2006 Nov; 152(5):876-81. PubMed ID: 17070148
[TBL] [Abstract][Full Text] [Related]
36. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial.
Gabriel HM; Oliveira JA; da Silva PC; da Costa JM; da Cunha JA
Catheter Cardiovasc Interv; 2006 Aug; 68(2):218-24. PubMed ID: 16817177
[TBL] [Abstract][Full Text] [Related]
37. Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials.
Kubica J; Koziński M; Navarese EP; Tantry US; Grześk G; Fabiszak T; Kubica A; Świątkiewicz I; Bliden KP; Gurbel PA
Cardiol J; 2012; 19(3):230-42. PubMed ID: 22641541
[TBL] [Abstract][Full Text] [Related]
38. Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
Bertrand OF; Rodés-Cabau J; Rinfret S; Larose E; Bagur R; Proulx G; Gleeton O; Costerousse O; De Larochellière R; Roy L
Am J Cardiol; 2009 Nov; 104(9):1235-40. PubMed ID: 19840568
[TBL] [Abstract][Full Text] [Related]
39. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial).
Dangas G; Aymong ED; Mehran R; Tcheng JE; Grines CL; Cox DA; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Lansky AJ; Stone GW;
Am J Cardiol; 2004 Oct; 94(8):983-8. PubMed ID: 15476608
[TBL] [Abstract][Full Text] [Related]
40. Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Lansky AJ; Pietras C; Costa RA; Tsuchiya Y; Brodie BR; Cox DA; Aymong ED; Stuckey TD; Garcia E; Tcheng JE; Mehran R; Negoita M; Fahy M; Cristea E; Turco M; Leon MB; Grines CL; Stone GW
Circulation; 2005 Apr; 111(13):1611-8. PubMed ID: 15811868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
